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Oxidative stress-induced retinal pigment epithelial (RPE) cell damage is an important factor in the pa-
thogenesis of age-related macular degeneration (AMD). Previous studies have shown that RTA 408, a
synthetic triterpenoid compound, potently activates Nrf2. This study aimed to investigate the protective
effects of RTA 408 in cultured RPE cells during oxidative stress and to determine the effects of RTA 408 on
Nrf2 and its downstream target genes. Primary human RPE cells were pretreated with RTA 408 and then
incubated in 200 μM H2O2 for 6 h. Cell viability was measured with the WST-8 assay. Apoptosis was
quantitatively measured by annexin V/propidium iodide (PI) double staining and Hoechst 33342 ﬂuor-
escent staining. Reduced (GSH) and oxidized glutathione (GSSG) were measured using colorimetric as-
says. Nrf2 activation and its downstream effects on phase II enzymes were examined by Western blot.
Treatment of RPE cells with nanomolar ranges (10 and 100 nM) of RTA 408 markedly attenuated H2O2-
induced viability loss and apoptosis. RTA 408 pretreatment signiﬁcantly protected cells from oxidative
stress-induced GSH loss, GSSG formation and decreased ROS production. RTA 408 activated Nrf2 and
increased the expression of its downstream genes, such as HO-1, NQO1, SOD2, catalase, Grx1, and Trx1.
Consequently, the enzyme activities of NQO1, Grx1, and Trx1 were fully protected by RTA 408 pre-
treatment under oxidative stress. Moreover, knockdown of Nrf2 by siRNA signiﬁcantly reduced the cy-
toprotective effects of RTA 408. In conclusion, our data suggest that RTA 408 protect primary human RPE
cells from oxidative stress-induced damage by activating Nrf2 and its downstream genes.
Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Age related macular degeneration (AMD), a leading cause of
blindness in the elderly, is a disease in which there is progressive
loss of central vision [1]. AMD occurs in two major forms, the dry
form and the wet form [2]. Anti-vascular endothelial growth factor
(VEGF) antibody therapy has revolutionized the treatment of wet
AMD [3]. However, dry AMD treatment remains a major challenge.
Currently, the only treatment for dry AMD is the use of the Age-
Related Eye Disease Study (AREDS)-based vitamin formulation,
which includes vitamin C, vitamin E, zinc oxide, cupric oxide, lu-
tein, and zeaxanthin [4,5]. However, this formulation does notaccess article under the CC BY-NC
arch Institute, University of
SA.reverse vision loss but only lowers the risk of developing advanced
stages of AMD in certain patients. Therefore, identifying novel
therapeutic targets and development of novel therapeutic mole-
cules for AMD are urgently needed.
Oxidative stress-induced retinal pigment epithelial (RPE) cell
death is an early event in the development of AMD [6]. The RPE
cells remain in a quiescent state throughout life. RPE cells present
at birth are constantly exposed to years of oxidative damage before
the onset of AMD. Therefore, RPE are very sensitive to oxidative
damage, often induced by external sources like UV light and in-
ternal sources like reactive oxygen species (ROS) produced by the
electron transport chain. Proteins are the main targets of free ra-
dicals due to their high abundance and their high reactivity with
ROS. As oxidative stress defense systems deteriorate with age,
oxidatively modiﬁed proteins gradually accumulate underneath
the RPE adjacent to the basement membrane and lead to drusen-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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the function of antioxidant pathways in the retina is critical for
developing new therapies for AMD.
One of the crucial antioxidant pathways involved is the nuclear
factor (erythroid-derived-2)-like 2 (Nrf2) pathway. Nrf2 is a
65 kDa molecule with a basic leucine zipper structure. Normally,
Nrf2 in its inactive state is kept in the cytoplasm bound to kelch-
like ECH-associated protein 1 (Keap1) [8,9]. With a half-life of only
20 min, Nrf2 is constantly targeted for ubiquitination by Keap1
with consequential degradation via the proteasome. When the cell
is in an oxidative stress environment, oxidative stress oxidizes
Keap1’s active site cysteine residues, preventing Keap1 from in-
teracting with Nrf2. With the accumulation of Nrf2 in the cyto-
plasm, Nrf2 moves to the nucleus where it binds to the small Maf
protein and the antioxidant response element (ARE). Activation of
ARE leads to the transcriptional activation of several other anti-
oxidant enzymes and proteins, such as NADPH dehydrogenase
(NQO1), heme oxygenase-1 (HO-1), glutaredoxin 1 (Grx1), and
thioredoxin 1 (Trx1) [10]. All these enzymes are distinguished by
their ability to reverse oxidative damage and stress. NADPH de-
hydrogenase transforms enzymes and proteins back into their
reduced state by the exchange of electrons between NADPH and
NADP [11]. HO-1 may be involved indirectly in the antioxidant
system by converting heme to other products such as iron (II),
carbon monoxide, and biliverdin [12]. Glutaredoxin and thior-
edoxin are two distinct yet similar systems. Although they are both
involved in reducing oxidized protein thiols and allowing proteins
to return to their functional state, Grx1 is considered as a vital
antioxidant enzyme, considering its essential locations in both the
cytoplasm [13,14], the intermembrane space of mitochondria [15],
and possibly, the nucleus. Therefore, drugs enabling and amplify-
ing the Nrf2 system are thought to be promising therapies for
AMD and other degenerative diseases that rely on the delicate
balance of oxidative species in the cell.
RTA 408 represents a novel class of therapeutics that has the
potential to increase Nrf2 expression and thereby increase ex-
pression of antioxidant enzymes. RTA 408 is a member of the
synthetic oleanane triterpenoid compounds. It is currently under
clinical investigation for the prevention of cataract surgery-in-
duced loss of corneal endothelial cells, prevention of radiation-
induced dermatitis in breast cancer patients undergoing radio-
therapy, treatment of solid tumors including melanoma and lung
cancer, and treatment of Friedreich’s Ataxia and mitochondrial
myopathies. Previous studies have demonstrated that RTA 408 has
signiﬁcant cytoprotective effects attributed to the activation of the
Nrf2 pathway [16–19]. The present study investigates the con-
nection between RTA 408 and the Nrf2 pathway as well as mul-
tiple antioxidant enzymes in RPE cells. This will help determine
whether RTA 408 may serve as a potent therapy for AMD and
other degenerative eye diseases.2. Methods
2.1. Materials
The 2-cyano-3,12-dioxooleana-1,9 (11)-dien-28-oic acid
(CDDO) derivative RTA 408 was 498% pure (Reata Pharmaceu-
ticals, Inc., Irving, TX, USA). Dulbecco’s modiﬁed Eagle’s medium
(DMEM), fetal bovine serum (FBS), penicillin/streptomycin, and
0.05% trypsin and other cell culture reagents were purchased from
Sigma-Aldrich (St. Louis, MO, USA). Hydrogen peroxide and other
chemicals were obtained from Sigma-Aldrich (St. Louis, MO, USA)
unless otherwise stated. Antibodies listed below were used: anti-
Nrf2 (Cell Signaling, Beverly, MA, USA, #12721), anti-NQO1 (Cell
Signaling, #3187), anti-Bax (Cell Signaling, #2772), anti-Bcl2 (CellSignaling, #2876), anti-cleaved caspase 3 (17 kDa) (Cell Signaling,
#9664), anti-HO-1 (Cell Signaling, #5061), anti-Grx1 (Abcam,
Cambridge, MA, USA, ab45953), anti-Trx1 (Abcam, ab86255), anti-
PSSG (Virogen, Watertown, MA, USA, 101-A-100), anti-SOD2 (sig-
nal, HPA001814), anti-catalase (Abcam, ab16731), anti-GAPDH
(Santa Cruz, Santa Cruz, CA, USA, sc-32233), anti-B23 antibodies,
and horseradish peroxidase-conjugated secondary antibodies
(sc2061, sc2060, sc2030; Santa Cruz Biotechnology, Santa Cruz, CA,
USA).
2.2. Human retinal pigment epithelial (RPE) cell culture
Human fetal RPE cells were purchased at passage one from
ScienCell™ Research Laboratories (Carlsbad, CA, USA), and all ex-
periments were performed with cells between passages two to
eight. The cells were maintained in DMEM supplemented with 10%
FBS, 100 μg/ml streptomycin, and 100 U/ml of penicillin. Cell cul-
tures were maintained at 37 °C in a humid atmosphere incubator
with 5% CO2 and 95% air. The mediumwas changed every 3-4 days.
For H2O2-induced apoptotic studies, cells were synchronized by
gradual serum deprivation with the following procedure: cells
were cultured overnight in DMEM with 2% FBS followed by in-
cubation in serum-free medium for 30 min before exposure to a
bolus of 200 mM H2O2 for 6 h.
2.3. Cell viability assay
Cell viability was measured by a colorimetric cell viability kit
(Promokine, Heidelberg, Germany) with the tetrazolium salt WST-
8 (2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-dis-
ulfophenyl)-2H-tetrazolium, monosodium salt), which can be
bioreduced to a water-soluble orange formazan dye by dehy-
drogenases present in the viable cells. The amount of formazan
produced is directly proportional to the number of living cells.
Cells were seeded at a density of 5000 cells/well (100 μl total
volume/well) in a 96-well assay. Cells were incubated with or
without RTA 408 (1–100 nM) for 24 h and then treated with
200 mM of H2O2 for 6 h. After treatment, 10 ml of WST-8 solution
was added to each well of the culture plate and incubated for 2 h
in the incubator. The absorption was evaluated at 450 nm using a
microplate reader (BioTek, Winooski, VT).
2.4. Hoechst 33342 ﬂuorescent staining
Cells were plated on poly-L-lysine coated glass coverslips for
overnight and then incubated with or without RTA 408 (1–100 nM)
for 24 h followed by 200 μM H2O2 treatment for 6 h. The cells were
washed twice with ice cold PBS and then ﬁxed with cold 4% paraf-
ormaldehyde for 15 min followed by PBS wash. The ﬁxed cells were
then stained with 0.1 mg/mL Hoechst 33342 (Invitrogen, Grand Is-
land, NY) for 10 min and rinsed with PBS. The images were taken
using a ﬂuorescence microscope (Olympus, Center Valley, PA).
2.5. Flow cytometry analysis of cell apoptosis
Cells were seeded in 100 mm culture plates and incubated
overnight at 37 °C and then incubated with or without RTA 408
(1–100 nM) for 24 h followed by 200 μM H2O2 treatment for 6 h.
After that, the cells were trypsinized and stained with annexin V
and PI using annexin V apoptosis Kit (Invitrogen, Grand island, NY)
according to the manufacturer’s protocol. The stained cells were
then analyzed by ﬂow cytometer (FC500, Beckman Colter, In-
dianapolis, IN) to differentiate among viable (annexin V/PI),
early apoptotic (annexin Vþ/PI), late apoptotic (annexin Vþ/PIþ)
cells, and necrotic cells (annexin V/PIþ).
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Intracellular ROS levels were determined using the ﬂuorescent
probe CellROX Orange Reagent (Life Technologies, city, state). After
pretreatment with RTA 408 for 24 h, RPE cells were exposed to
200 μM H2O2 for another 30 min. After treatment, the cells were
loaded with 5 mM CellROX Orange Reagent for 30 min at 37 °C,
washed with DPBS and immediately imaged on a ﬂuorescence
microscope (Olympus, Center Valley, PA). The cellular ﬂuorescence
was quantiﬁed using the ImageJ software, after background sub-
traction for each image.
2.7. GSH and GSSG assays
Cells were collected on ice using cell scrapers and were lysed
with RIPA buffer (Sigma, St. Louis, MO, USA). For glutathione (GSH)
measurement, an aliquot of fresh cell lysate was treated with an
equal volume of 20% trichloroacetic acid followed by centrifuga-
tion. The supernatant was used immediately for GSH analysis
using Ellman’s (5,5’-dithiobis-(2-nitrobenzoic acid)) reagent, fol-
lowing the method of Lou et al. [20]. GSSG level was measured by
using a oxidized glutathione (GSSG) assay kit (Abcam, Cambridge,
MA, USA) according to the manufacturer’s instruction.
2.8. Western blot analysis
Protein concentration was determined with a BCA assay kit
(Thermo Scientiﬁc, Rockford, IL). Equal amounts of protein were
boiled in Laemmli buffer (Bio-Rad, Bio-Rad, Richmond, CA, USA) and
loaded onto 12% SDS-PAGE gel and transferred to a 0.2 mm poly-
vinylidene diﬂuoride membrane (GE Healthcare, Boulder, CO). The
membranes were incubated with appropriate primary antibodies for
overnight at 4 °C and were then incubated with the appropriate
secondary antibodies for 1 h. Detection was performed using the ECL
Western blotting detection system (Thermo Scientiﬁc, Rockford, IL).
The immunoblot was analyzed with a Bio-Rad imaging system
(Versadoc 5000 MP Imaging System, Bio-Rad, Richmond, CA, USA).
2.9. Nrf2 translocation
Cells were treated without and with RTA 408 for 0.5, 2, and 6 h.
The cytoplasmic and nuclear fractions of each sample were ob-
tained using the NE-PER Nuclear and Cytoplasmic Extraction Re-
agents from Thermo Scientiﬁc (Thermo Scientiﬁc, Rockford, IL).
60 μg of each sample was loaded onto a 12% SDS-PAGE gel and
transferred onto a PVDF membrane. The membranes were in-
cubated with Nrf2 antibody for overnight at 4 °C and were then
incubated with the appropriate secondary antibodies for 1 h. β-
actin and B23 were used as cytoplasmic and nuclear marker, re-
spectively. Detection was performed using the ECL Western blot-
ting detection system (Thermo Scientiﬁc, Rockford, IL). The im-
munoblot was analyzed with a Bio-Rad imaging system (Versadoc
5000 MP Imaging System, Bio-Rad, Richmond, CA, USA).
2.10. Protein glutathionylation detection
Cells were pretreated with or without 100 nM RTA 408 for 24 h
and then incubated with 1 mM H2O2 for 30 min and lysed with
RIPA buffer (Sigma). Equal amounts of protein (80 μg) from each
group were loaded onto an SDS-PAGE gel under non-reducing (no
β-mercaptoethanol) conditions, immunoblotted, and probed with
an anti-PSSG antibody, which previously has been shown to se-
lectively recognize glutathionylated proteins [21–23].2.11. Enzyme activity assays
Grx1 was assayed using 2-Hydroxyethyl disulﬁde (HEDS) as the
substrate according to the method described in Raghavachari and
Lou [24]. In brief, the cell lysate was mixed with potassium
phosphate buffer (200 mM, pH 7.5) containing 0.5 mM glutathione
(GSH), 0.4 U/mL glutathione reductase (GR), 0.2 mM β-nicotina-
mide adenine dinucleotide phosphate, reduced tetra (cyclohex-
ylammonium) salt (NADPH), and 2 mM hydroxyethyl disulﬁde
(HED). The reaction was carried out at 30 °C, and the decrease
in absorbance at 340 nm was monitored for 5 min and used to
determine the Grx1 activity. Trx1 activity was determined using
the methods of Holmgren and Bjornstedt [25]. The cell lysate was
mixed with potassium phosphate buffer (100 mM, pH 7.0, with
2 mM EDTA) containing 0.05 U/mL thioredoxin reductase (TR),
0.2 mM NADPH, and 0.14 mM insulin. The reaction was carried out
at 30 °C, and the decrease in absorbance at 340 nmwas monitored
for 5 min and used to determine the Trx1 activity. NQO1 activity
was measured using NQO1 activity assay kit (Abcam) according to
manufacturer’s instructions.
2.12. SiRNA transfection
Control and Nrf2 siRNA used in this study were chemically
synthesized by Santa Cruz Biotechnology (Santa Cruz, CA, USA).
SiRNA duplexes (scrambled siRNA, sc-37007; Nrf2 siRNA, sc-
72089) were transfected into primary human RPE cell with siRNA
transfection reagent (sc-29528; Santa Cruz, CA, USA) according to
the manufacturer’s instructions.
2.13. Statistics
Each experiment was performed at least three times and sta-
tistical analyzes were performed using Student’s t-test when
comparing between two groups and one-way ANOVA followed by
Bonferroni’s test as a post hoc test when comparing among three
or more groups with the Prism software (GraphPad, La Jolla, CA).
The number of experimental samples used in each group is pre-
sented in the. All data are expressed as means7SD and differ-
ences were considered signiﬁcant at Po0.05.3. Results
3.1. RTA 408 inhibits H2O2-induced cytotoxicity in RPE cells
RTA 408 at concentrations 1 to 100 nM had no apparent cyto-
toxic effects on RPE cells (Fig. 1A). To examine the cytotoxicity of
H2O2, RPE cells were treated with different concentration of H2O2
(100–500 μM) for 6 h followed by a cell viability assay. As shown
in Fig. 1B, H2O2 dose-dependently inhibited RPE cell survival.
200 uM of H2O2, which induced around 60% of cell viability loss,
was used in the following experiments. To investigate the cyto-
protective effects of RTA 408, RPE cells were pretreated with 1–
100 nM of RTA 408 for 24 h followed by addition of 200 uM H2O2
for 6 h. Pretreatment with 1, 10, and 100 nM RTA 408 increased
cell viability to 52.771.2% (mean7SD, n¼6, Po0.01), 80.173.1%
(Po0.01), and 95.472.8% (Po0.01), respectively (Fig. 1C).
3.2. Anti-apoptotic effects of RTA 408
To better understand the anti-apoptotic effect of RTA 408, cell
apoptosis was evaluated by two different assays: Hoechst 33342
nuclei staining and Annexin V/PI double staining. As shown in
Fig. 1D, the control and RTA 408 alone groups both showed normal
nuclear morphology with uniform blue chromatin and organized
Fig. 1. RTA 408 protected primary human RPE cells against H2O2-induced oxidative damage and cell death. (A) Lack of RTA 408 cytotoxicity in RPE cells. Cell viability from
different concentrations of RTA 408 treated (1, 10, and 100 nM), non-treated (control), and vehicle (DMSO-treated) RPE cells was measured by WST-8 assay. Each value is
expressed as the mean7SD (n¼6). (B) Dose-dependent effect of H2O2 on the viability of RPE cells. Cells were exposed to 0, 100, 200, 300, 300, 400, or 500 mM H2O2 for 6 h.
Viable cells were quantiﬁed byWST-8 assay. *Po0.05, **Po0.01, ***Po0.001 comparing with the 0 μMH2O2 group. (C) Cytoprotective effects of RTA 408. RPE cells were ﬁrst
pretreated with 1 nM, 10 nM, and 100 nM of RTA 408 for 24 h and then incubated in 200 uM H2O2 for 6 h. Control and vehicle (DMSO-treated) groups were also incubated in
200 uM H2O2 for 6 h as well for comparison to RTA 408 treated groups. Cell viability was measured via the WST-8 assay and represented by mean7SD. ***Po0.001
comparing with the H2O2 alone group. (n¼6) (D) Cell apoptosis in RTA 408 treated cells. RPE cells were ﬁrst pretreated with or without 100 nM RTA 408 for 24 h and then
incubated in 200 uM H2O2 for 6 h. Cells were then subjected to Hoechst staining. Apoptotic cells are labeled with white arrows as having a nuclear shrinkage or strong
ﬂuorescence, (n¼3).
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Fig. 2. RTA 408 decreases apoptotic cell death in H2O2-treated RPE cells. (A) Flow cytometry of annexin/PI double stained of control, RTA 408 treatment only, H2O2-treated only, and RTA
408 and H2O2-treated RPE cells, showing live cells in quadrant A3, early apoptotic cells in quadrant A4, late apoptotic cells in quadrant A2, and necrosis in quadrant A1. Representative
ﬁgures showing population of viable (annexin V/PI), early apoptotic (annexin Vþ/PI), late apoptotic (annexin Vþ/PIþ) and necrotic (annexin V/PIþ) cells. Bar graphs showing
the quantiﬁcation of early (B) and late apoptotic (C) cells. Data were mean7SD of three independent experiments. ***Po0.001 compared with H2O2 only group, (n¼3).
X. Liu et al. / Redox Biology 8 (2016) 98–109102structure. After adding 200 μM H2O2 for 6 h, RPE cells showed
condensed nuclei, increased ﬂuorescent intensity, and fragmented
chromatin (labeled with arrows). In contrast, 100 nM RTA 408 ef-
fectively prevented H2O2-induced nuclear changes as indicated by
less nuclear fragmentation and condensation. To further conﬁrm the
anti-apoptotic effects of RTA 408, annexin V/PI double staining and
ﬂow cytometry analysis were performed to quantify early (annexin
Vþ/PI-) or late apoptotic (annexin Vþ/PIþ) cells. The representative
images for ﬂow cytometry and the summarized data are presented
in Fig. 2. Cell apoptosis levels were similarly low in control and RTA
408 treatment alone cells. However, after H2O2 treatment, the rate of
early apoptosis increased to 30.575.6% but remained very low
(4.670.5%) in the RTA 408 pretreated group (Po0.05) (Fig. 2B).
Consistently, after exposure to H2O2, the number of late apoptotic
cells increased to 13.773.3%, and pretreatment with RTA 408 re-
duced the percentage of late apoptosis to 2.171.2% (Fig. 2C).
3.3. RTA 408 inhibits Bax and caspase 3 activation and upregulates
Bcl-2
The pro-apoptotic protein Bax initiates cell apoptosis bydirectly binding with Bcl-2, thus antagonizing the anti-apoptotic
effect of Bcl-2. Under oxidative stress, Bax undergoes a con-
formational change and translocates from the cytosol to the mi-
tochondrial membrane, leading to the release of cytochrome C and
activation of caspase 3 [26]. Therefore, the Bax/Bcl2 ratio and
caspase 3 cleavage were measured to further conﬁrm the anti-
apoptotic effect of RTA 408. As demonstrated in Fig. 3A and B,
protein level of anti-apoptotic factor Bcl-2 was suppressed by
80% after H2O2 treatment. However, 100 nM RTA 408 could block
the oxidative stress mediated reduction in Bcl-2 expression. In
contrast, the pro-apoptotic Bax increased to three fold over control
after 200 μM H2O2 treatment. The increased level of Bax was
signiﬁcantly inhibited by pretreatment with 100 nM RTA 408
(Fig. 3A and C). Furthermore, caspase 3 protein was not detected in
control cells; however, oxidative stress-induced caspase 3 cleavage
as seen by the appearance of caspase 3 positive band at 17 kDa in
H2O2-treated cells but not in the RTA 408 pretreated group (Fig. 3A
and C). These results indicate that RTA 408 treatment strongly
protected RPE cells from H2O2-induced apoptosis.
Fig. 3. Effects of RTA 408 treatment on Bcl-2, Bax, and caspase 3 levels. (A) Whole cell lysates of control (no H2O2 treatment), H2O2-treated, and both RTA 408 and H2O2-treated
RPE cells were prepared, and 60 ug of each protein sample was subjected to SDS-PAGE and then blotted onto a PVDF membrane. The blot was incubated with Bcl2, Bax, and
cleaved caspase 3 antibodies. GAPDH was used as a reference control for equal protein loading. (B) Quantitative analysis of Bcl2 protein expression levels in all treatment
groups are represented as mean7SD. (C) Quantitative analysis of Bax protein levels in all treatment groups are represented on a bar graph as mean7SD. (D) Quantitative
analysis of western blot data of cleaved caspase 3 shown in bar graph form, ***Po0.001, comparing H2O2 only group, (n¼3).
Fig. 4. RTA 408 signiﬁcantly reduces reactive oxygen species (ROS) production in H2O2-treated RPE cells. RPE cells were pretreated with or without 1 nM, 10 nM, and 100 nM RTA
408 for 24 h followed by 200 mM H2O2 treatment for 30 min. Fluorescence was detected using the probe CellROX Orange reagent for all groups and control (no H2O2
treatment) cells. Fluorescence intensity is quantiﬁed and represented as mean7SD via a bar graph, ***Po0.001 compared with H2O2 only group, (n¼3).
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Intracellular ROS levels were measured by preloading the cells
with CellROX Orange followed by stimulating with H2O2 to
monitor the resulting ROS sensitive ﬂuorescent product. Fig. 4
shows the ﬂuorescence in the live RPE cells by confocal micro-
scopy 30 min after H2O2 exposure. No ﬂuorescence could be de-
tected at the same time interval in the control cells where no H2O2
was added (Fig. 4A). H2O2 treatment for 30 min induced a massive
production of ROS (Fig. 4B). RTA 408 signiﬁcantly suppressed ROS
production in a dose-dependent manner (Fig. 4C–E). Quantitative
ﬂuorescence intensities of CellROX Orange in the various groups
are shown in Fig. 4F.
3.5. Preservation of the redox state in RTA 408 treated RPE cells
The glutathione disulﬁde-glutathione couple (GSSG/GSH) can
serve as an important indicator of cellular redox environment.
After H2O2 treatment, the intracellular GSH levels in RPE cells were
signiﬁcantly decreased from 25.672.9 to 5.272.1 nmol/mg pro-
tein (Fig. 5A). However, only less than a 10% decrease in GSH levels
was observed in RTA 408 pretreated cells after H2O2 exposure. RTA
408 treatment alone slightly increased GSH level to
35.276.5 nmol/mg. On the other hand, the level of GSSG was
signiﬁcantly increased in response to H2O2 but remained relatively
low in RTA 408 pretreated cells (without RTA 408 pretreatment:
2.470.3 vs RTA 408 treatment: 1.270.3 nmol/mg protein,
Po0.05) (Fig. 5B). RTA treatment alone had no apparent effect on
cellular GSSG levels. Furthermore, H2O2 treatment caused a sig-
niﬁcant increase in protein glutathionylation, an index of protein
cysteine thiol oxidation. Pretreatment with 100 nM RTA 408Fig. 5. Effects of RTA 408 treatment on levels of GSH, GSSG, and protein-GSH mixed disulﬁ
200 μM H2O2 challenge for 6 h. GSH levels (A), GSSG levels (B) were measured as descr
levels in RTA 408 pretreated cells. The cells were treated with 1 mM H2O2 for 30 min and
mercaptoethanol) for western blot analysis using an anti-PSSG antibody. (D) The relative
independent experiments, **Po0.01, and ***Po0.001, comparing with H2O2 only groupsigniﬁcantly inhibited the H2O2-induced protein glutathionylation
by 60% (Fig. 5C,D).
3.6. RTA 408 activates Nrf2 and its downstream genes in RPE cells
To investigate the effect of RTA 408 on Nrf2 and its downstream
genes, cells were treated with RTA 408 at 1, 10, and 100 nM for
24 h. Western blot analysis indicated a dose-dependent increase of
Nrf2, HO-1, NQO1, SOD2, catalase, Grx1, and Trx1 protein expres-
sion (Fig. 6A). When cells were treated with 100 nM RTA 408 for
various time, Nrf2 and its downstream targets were upregulated as
early as 6 h after RTA 408 treatment and lasted for at least 24 h
(Fig. 6B). RTA 408 also enhanced Nrf2’s nuclear translocation. In
the cytoplasm, Nrf2 expression slowly decreased, as more Nrf2
accumulated and progressively moved into the nucleus (Fig. 6C
and D). This data veriﬁes that RTA 408’s main protective me-
chanism is through Nrf2 activation.
3.7. RTA 408 increases NQO1, Grx1, and Trx1 activities
To further investigate the effects of RTA 408 on Nrf2 down-
stream target genes, the enzyme activities of Grx1, Trx1, and NQO1
were examined. The activities of Grx1 and Trx1 in normal RPE cells
were 5.871.1 and 4.270.4 mU/mg protein, respectively. When
cells were exposed to H2O2, Grx1 was slightly decreased to below
35% of the initial activity but was restored up to 95% of its normal
level when pretreated with RTA 408 (Fig.7A). Similarly, H2O2
treatment caused a signiﬁcant decrease in Trx1 activity to 50%
control levels, and RTA 408 pretreatment (100 nM for 24 h) pro-
vided a full protection (Fig. 7B). As shown in Fig. 7C, strong pro-
tection was also observed for NQO1 activity in RTA 408 pretreatedde (PSSP) levels. Cells were pretreated with 100 nM RTA 408 for 24 h followed by
ibed in Materials and Methods. (C) Comparison of protein glutathionylation (PSSG)
total proteins were separated on a 12% SDS-gel under non-reducing condition (no β-
pixel density of all the PSSG bands compared to β-actin. Data are mean7SD of three
, (n¼3).
Fig. 6. Effects of RTA 408 on expression of Nrf2 and downstream genes. (A) Dose-dependent effects of RTA 408 on Nrf2 and downstream gene expression. RPE cells were
pretreated with 1–100 nM RTA for 24 h. Control cells were treated identically, but without addition of RTA 408. Whole cell lysates of each group were prepared, and 60 ug of
each protein sample was used to detect the levels of Nrf2, SOD2, catalase, NQO1, HO-1, Grx1, and Trx1 by western immunoblotting. GAPDH was used as a loading control.
(B) Time-dependent effects of RTA 408 on Nrf2 and its downstream gene expression. Cells were treated with 100 nM RTA for various time (0–24 h). 60 μg of each protein
sample was subjected to western immunoblot analysis. The blot was incubated with GAPDH, Nrf2, SOD2, catalase, NQO1, HO-1, Grx1, and Trx1 antibodies. GAPDH was used
as a reference for equal protein loading. All experiments were repeated three times with similar results. (C) Nrf2 expression in the cytoplasmic and nuclear fractions. Cells
were treated with 100 nM of RTA 408 for various time points (0, 0.5, 2 and 6 h) and then were separated to its nuclear and cytoplasmic portions using a kit. 40 μg of each
sample were subjected to western immunoblot analysis and incubated with B23, Nrf2, and β-actin antibodies. All experiments were repeated three times with similar results.
(D) Quantitative analysis of time-dependent Nrf2 translocation are depicted as mean7SD, **Po0.01, and ***Po0.001, comparing control (0 h) group (n¼3).
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whereas RTA 408 pretreatment almost completely protected
NQO1 from H2O2-induced inactivation.
3.8. Nrf2 siRNA abolishes the cytoprotective effects of RTA 408
SiRNA was used to conﬁrm that RTA 408-induced Nrf2 activa-
tion protects cells from H2O2-induced cell injury. Nrf2 siRNA-
treated groups showed lower levels of Nrf2 as compared to
scrambled siRNA transfected and non-transfected control cells(Fig. 8A and B). Under non-stressed condition, Nrf2 inhibition
slightly lowered RPE cell viability. When cells were challenged
with H2O2, Nrf2 siRNA transfected cells had a much lower survival
rate compared with that of scrambled siRNA transfected cells.
Furthermore, as shown in Fig. 8C, the cytoprotective effect of RTA
408 was signiﬁcantly blocked by the Nrf2 siRNA, indicating RTA
408 promotes cell survival through Nrf2 activation.
4. Discussion
Age-related macular degeneration (AMD) is a leading cause of
Fig. 7. Effects of RTA 408 on Grx1, Trx1, and NQO1 enzyme activities. RPE cells were
pretreated with 100 nM RTA 408 for 24 h followed by 200 μM H2O2 for another 6 h.
Quantitative analysis of Grx1 (A), Trx1 (B), and (C) NQO1 activity of all treatment
groups (control, H2O2-treated, RTA 408 and H2O2-treated, and 100 nM RTA 408
only RPE cells) are depicted as mean7SD, **Po0.01, and ***Po0.001, comparing
H2O2 only group (n¼3).
Fig. 8. Nrf2 knockdown abolished the cytoprotective effects of RTA 408 in RPE cells.
RPE cells were transfected with or without scrambled or Nrf2 siRNA for 48 h, then
incubated with or without 100 nM RTA 408 for 24 h, followed by 200 μM H2O2
treatment for another 6 h. (A) Western blot analysis of Nrf2 protein levels. Total
60 mg of protein of each sample was subjected to Western blot with Nrf2 and
GAPDH antibodies. (B) Bar graph of western blot data showing Nrf2 protein ex-
pression normalized to GAPDH expression. Values are the mean7SD, ***Po0.001
comparing scramble siRNA group, (n¼6). (C) Cell viability was measured in RPE
cells transfected with or without Nrf2 siRNA. Values are the mean7SD, **Po0.01,
and ***Po0.001, comparing scramble siRNA group (n¼6).
X. Liu et al. / Redox Biology 8 (2016) 98–109106irreversible blindness and loss of central vision. Dry AMD has no
known current treatment and can account for nearly 90% of all
AMD cases, highlighting the importance of ﬁnding a good therapy
for treating this form of AMD [1]. Because oxidative stress plays a
signiﬁcant role in AMD pathogenesis, antioxidant therapy has
been a novel proposed solution in treating AMD [6]. Speciﬁcally,
reinforcing the cellular defense systems that protect the retina andRPE cells against oxidative stress is a viable option for preventing
and/or reducing the progression of macular degeneration. Our data
show that RTA 408 protects RPE cells from oxidative stress-in-
duced cell death, and this protective mechanism is related to Nrf2
activation. The present study demonstrated that: (1) RTA 408
protected primary human RPE cells from H2O2-induced cell death
in a dose- and time-dependent manner. (2) RTA 408 inhibited pro-
apoptotic factors like Bax and caspase 3 and promoted anti-
apoptotic factors like Bcl-2. (3) RTA 408 pretreatment restored the
redox state in oxidatively damaged cells as indicated by less ROS
production, higher GSH levels, and less protein glutathionylation.
(4) In nanomolar ranges, RTA 408 potently activated the expres-
sion of Nrf2 and its downstream targets SOD2, catalase, NQO1, HO-
1, Grx1, and Trx1.
X. Liu et al. / Redox Biology 8 (2016) 98–109 107Nrf2 is a basic leucine zipper transcription factor which binds
to a promoter sequence known as the antioxidant-responsive
element (ARE), leading to coordinated induction of a battery of
cytoprotective and antioxidant genes [10]. Increased Nrf2 activity
has often correlated with cellular survival and protection. Johnson
and others have shown previously that Nrf2 activation can protect
against oxidative injury to the RPE [27,28]. Conversely, mice that
are deﬁcient of Nrf2 developed pathological features similar to
human AMD [29]. These data strongly suggest that Nrf2-mediated
signaling pathways are essential in protecting the RPE cells against
aging and age-related degeneration. As such, Nrf2-activating drugs
are of current interest in the treatment of AMD.
In particular, RTA 408 is a triterpenoid CDDO derivative that
reversibly and covalently modiﬁes reactive cysteine residues on
multiple proteins including Keap1, the negative regulator of Nrf2.
Binding of RTA 408 to Cys151 in Keap1 results in Keap1 inhibition,
thereby activating the Nrf2 signaling pathway and its downstream
target genes to protect many different tissues from various toxic
insults [30]. For example, Reisman et al. reported that topical ap-
plication of RTA 408 protected mice from radiation-induced der-
matitis by a Nrf2-induced cytoprotective response [17,18]. They
also found that RTA 408 provided robust radiation protection to
the murine gastrointestinal and hematopoietic system and im-
proved overall survival of irradiated mice [18]. As well as inducing
protection of normal tissues, RTA 408 was also shown to inhibit
human prostate cancer xenograft growth in mice [19]. More re-
cently, it has been proposed that RTA 408 may address and treat
ophthalmic disorders. For example, a phase II clinical trial is on-
going to test an RTA 408 ophthalmic suspension for the prevention
of corneal endothelial cell loss following cataract surgery. Al-
though several studies have indicated that RTA 408 is a potent
cytoprotective agent in multiple different cell types, our experi-
ment is the ﬁrst to show its protective function in human RPE cells
against oxidative stress.
Activation of Nrf2 by RTA 408 upregulates multiple enzymes
and proteins capable of detoxifying electrophiles and ROS, which
simultaneously prevents oxidative damage to critical macro-
molecules like proteins, DNA, or lipids. RTA 408 also decreases
ROS-mediated activation of pro-inﬂammatory transcription fac-
tors. Nanomolar concentrations of RTA 408 promoted cellular
protection and survival and eliminated oxidative stress-induced
RPE cell injury demonstrating high potency and efﬁcacy in these
assays. Compared to other RPE protective agents such as sulfor-
aphane [31,32], lipoic acid [33,34], and sulindac [35], RTA 408
required much lower doses to exert cytoprotective effects. Fur-
thermore, Nrf2 activation can also cause other ROS scavenging
activities and upregulation of key cytoprotective molecules such as
GSH and the glutaredoxin systems [8,36]. As the most abundant
low molecular weight thiol-containing molecule, GSH takes an
active part in scavenging ROS, both by direct reaction with ROS
and as the cofactor of other antioxidant enzymes, including glu-
tathione peroxidase and Grx1 [14]. Once oxidized, GSH is con-
verted into GSSG and GSH/GSSG ratio decreases, which further
leads to protein glutathionylation. Protein glutathionylation, de-
ﬁned as the reversible formation of a mixed disulﬁde (PSSG) be-
tween protein thiols and glutathione (GSH), appears to be the
most important mode of thiol oxidation [37]. In high oxidative
stress environments, protein glutathionylation accumulates,
causing protein inactivation, damage, and eventually cell death
[13,14]. However, RTA 408 treatment diminished protein glu-
tathionylation and increased GSH levels, enhancing the redox state
of RPE cells. Therefore, RTA 408 may have the potential to prevent
or reverse oxidative damage commonly found in AMD and other
retinopathies.
Our data in Fig. 6C strongly supports RTA 408’s ability to sti-
mulate the Nrf2 pathway, as RTA 408 treatment signiﬁcantlyincreased Nrf2 accumulation and translocation into the nucleus.
This is the primary mechanism for how RTA 408 exerts its pow-
erful antioxidant effects. Following the treatment of primary RPE
cells with RTA 408, we also observed signiﬁcant increases in phase
II enzymes including SOD2, catalase, NQO1, HO-1, Grx1, and Trx1.
Grx1 belongs to the oxidoreductase family and is a component of
the endogenous antioxidant defense system [38]. Grx1 is critical
for protecting human RPE cells against oxidative damage, and our
previous study has shown that Grx1 prevented oxidative stress-
induced protein glutathionylation [14]. The protective effect of
Grx1 is also associated with its ability to prevent oxidative stress-
induced AKT glutathionylation and thus stimulate AKT activation, a
pathway involved in the transcription of several survival and
protective genes [14]. Another powerful and crucial oxidor-
eductase that functions similarly to Grx1, Trx1 can reverse protein
oxidation that results in disulﬁde bonds and cause cellular pro-
tection. Trx1 upregulation has corresponded with anti-apoptotic
effects and cell survival [39,40]. Working closely together, SOD2
and catalase are vital enzymes involved in the detoxiﬁcation of
hydrogen peroxide and superoxide, both extremely damaging
molecules involved in AMD [41–44]. Another Nrf2 downstream
target and powerful indirect antioxidant enzyme, HO-1 can also
convert heme to beneﬁcial byproducts such as carbon monoxide
and bilirubin that can directly scavenge free radicals and repair
DNA damage caused by oxidative stress [12,28]. RTA 408 also sti-
mulates NQO1 expression, another extremely important enzyme
that reduces oxidized proteins and promotes a better cellular re-
dox state.
The Nrf2 activation capabilities of RTA 408 also affect the
apoptotic pathway by decreasing the expression of pro-apoptotic
Bax and stimulating anti-apoptotic Bcl2 during oxidative insults.
The cytoprotective effects of RTA 408 was also seen by Annexin V/
PI double staining. These data clearly show that H2O2 mediated
RPE apoptosis and necrosis was signiﬁcantly decreased by treat-
ment with RTA 408. Overall, RTA 408 enhanced antioxidant and
survival proteins’ expression by stimulating Nrf2 activation, lead-
ing to the prevention and reversal of damage generated by oxi-
dative insults.
To speciﬁcally show that RTA 408 was involved in the Nrf2
signaling pathway, we decided to observe the effect of RTA 408 on
cell viability and Nrf2 downstream proteins in Nrf2-deﬁcient cells.
Therefore, we knocked down Nrf2 using a speciﬁc siRNA and found
that the induction of HO-1 and NQO1 by RTA 408 was inhibited;
this result conﬁrmed previous conclusions regarding the regula-
tion of phase II enzymes by Nrf2. In an oxidative stress environ-
ment, Nrf2-deﬁcient RPE cells died despite RTA 408 treatment.
Considering that we did not use siRNA to inhibit other Nrf2
downstream genes or GSH synthesis enzymes and view how it
affected RTA 408's effectiveness, we cannot rule out other possible
pathways but will make sure to address these limitations in our
future studies. Overall, these data signiﬁcantly support our hy-
pothesis that RTA 408 is a potent Nrf2 activator that can enhance
RPE survival and protection.
In conclusion, as summarized in Fig. 9, our results strongly
suggest that RTA 408 can activate the Nrf2 pathway and induce
phase II enzyme expression, thereby protecting RPE cells from
oxidative stress-induced cell apoptosis, preventing ROS over pro-
duction, and inhibiting protein oxidation. The potency and efﬁcacy
of RTA 408 in protecting RPE cells makes it an attractive candidate
for potential clinical use in treating oxidative stress-related retinal
degenerative disease. In our future studies, we hope to replicate
the success of RTA 408 in an in vivo AMD disease model to further
inspire the use of Nrf2-activating drugs to treat oxidative stress-
related degenerative eye diseases.
Fig. 9. RTA 408 activates the Nrf2 pathway which leads to an upregulation of antioxidant enzymes and protects the cell from oxidative stress. Binding of RTA 408 to Cys151 in
Keap1, the negative regulator of Nrf2, results in Keap1 inhibition. This promotes Nrf2 movement into the nucleus where it binds to the antioxidant response element (ARE).
With the activation of ARE, transcriptional activation of antioxidant enzymes heme oxygenase-1 (HO-1), NADPH dehydrogenase (NQO1), superoxide dismutase 2 (SOD2),
catalase, thioredoxin 1 (Trx1), and glutaredoxin 1 (Grx1) occurs. HO-1 converts heme to carbon monoxide, iron (II), and biliverdin, which all indirectly scavenge ROS. NQO1
converts enzymes and other proteins (R) back to their reduced form (RH) through the electron transfer between NADPH and NADP. Superoxide (O2) can be converted to
hydrogen peroxide using SOD2 and then further processed into water by catalase. Grx1 and Trx1 work together to reduce protein-glutathione mixed disulﬁde (PSSG) and
protein-protein disulﬁde (PSSP) to protect protein thiols from oxidation. Overall, RTA 408 induction of phase II antioxidant enzymes such as HO-1, NQO1, SOD2, catalase,
Grx1, and Trx1 via activation of Nrf2 promote RPE cell survival during oxidative stress.
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